Abstract
Introduction

Systemic sclerosis (SSc) is an autoimmune disease of unknown aetiology that affects the skin and various internal organs. The most obvious histological feature of SSc is a massive accumulation of extracellular matrix components such as collagens,
glycosaminoglycans and fibronectin [1] . The [2, 3] 
. Imatinib is a small molecule inhibitor that binds to the ATP-binding pocket of abelson kinase (c-abl) and blocks efficiently its tyrosine kinase activity. C-abl is an important downstream signalling molecule of TGF␤ that mediates the profibrotic effects of TGF␤ independent of Smad 3/4 [2]. In addition to its effects on c-abl, imatinib mesylate blocks the tzyrosine kinase
Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo
Material and methods
Cell culture
Immortalized human microvascular endothelial (HMEC-1) cells were cultured as described previously [8] .
Incubation with imatinib mesylate
HMEC-1 cells were incubated with imatinib mesylate in concentrations from 0.001 to 1.0 g/ml for 24-96 hrs. These concentrations correspond to the mean plasma peak and trough concentrations in human beings after administration of standard doses of imatinib [2, 3] .
Caspase 3 activity assay
The activities of caspase-3-like proteases were determined using the EnzChek caspase-3 assay kit (Invitrogen, Karlsruhe, Germany) as described [9] . 
Microtitre tetrazolium (MTT) assay
The metabolic activity of HMEC-1 cells incubated with imatinib for 24-96 hrs was assessed using the MTT [3, (4,5- 
Generation of proliferation curves
Scratch assay
Confluent monolayers of HMEC-1 cells were wounded by scratching the surface uniformly with a pipette tip. The migration of cells into the scratched area was photographically monitored using the Spot Insight QE camera. Shortening of the distance between the two borders of the scratch was determined at three defined sites per sample after 0, 24 and 48 hrs.
Chemotaxis assay
The effect of imatinib on the chemotaxis of HMEC-1 cells was determined with a transwell chemotaxis assay using 24-well cell culture inserts with the bottom sealed by an 8-m pore polycarbonate-filter (Becton Dickinson). The number of cells that migrated through the filter to the lower compartment was quantified after 36 hrs with a FACS Calibur flow cytometer (Becton Dickinson).
In vitro capillary morphogenesis assay
To assess the influence of imatinib on the formation of tubes, an in vitro capillary morphogenesis assay was performed as described previously [10] . Tube (Fig. 1A) . Incubation of HMEC-1 cells with increasing concentrations of imatinib did also not increase the number of annexin V positive, apoptotic cells (Fig. 1B) (Fig. 1D) . Imatinib did also not increase the time period needed to reach 100% confluence. Fig. 2A and B) . The time until closure of the scratch was also not prolonged.
Results
Confirmation of the potent biologic effects of imatinib
Effects of imatinib on the viability and proliferation of endothelial cells
Potential effects of imatinib mesylate on the metabolic activity and proliferation of endothelial cells were analysed by MTT assay and by generating proliferation curves. No differences in metabolic activity were observed with the MTT assay between HMEC-1 cells treated with imatinib for 24-96 hrs and untreated controls (Fig. 1C). Incubation with imatinib in pharmacologically relevant concentrations for up to 96 hrs also did not alter cell counts
Expression of markers for vascular activation by imatinib-treated endothelial cells
ICAM-1, VCAM-1, endothelin-1 and VEGF are differentially expressed in SSc and are common markers of endothelial cell activation. Incubation of HMEC-1 cells with imatinib did not change the expression of ICAM-1, VCAM-1, endothelin-1 and VEGF (data not shown), suggesting that imatinib might not alter the activation of endothelial cells. HMEC-1 cells expressed mRNA for PDGF recptor ␣ (PDGFR␣), PDGFR␤ and c-kit, which are established targets of imatinib. Incubation with imatinib did not alter the expression of these genes in HMEC-1 cells (data not shown).
Effects of imatinib on migration, chemotaxis and tube forming
To assess whether imatinib reduces the migration of endothelial cells, scratch assays were performed. No differences in the distance between the two borders of the scratch were observed in HMEC-1 cells incubated with imatinib compared with untreated controls after 24 hrs and 48 hrs (
To study the effects of imatinib on chemotaxis of endothelial cells, a microchemotaxis assay was performed. Imatinib did not reduce the number of migrated HMEC-1 cells (Fig. 2C) .
Next, we analysed whether imatinib inhibits tube formation using an in vitro capillary morphogenesis assay. Imatinib did not reduce the number of tubes, the maximal length of the capillary tubes or the number of branching points (Fig. 2) , suggesting that imatinib does not affect tube formation in vitro. (Fig. 3) [5, 11, 12] [14] [15] [16] . Another concern might the potential risk of cardiotoxicity as a small number of patients developed cardiomyopathy while on imatinib [17, 18] .
Fig. 1 Imatinib does not induce apoptosis, reduce the metabolic activity or decrease proliferation of endothelial cells. (A and B) Incubation with imatinib in concentrations from 0.001 to 1.0 g/ml for 24 hrs did not increase the activity of caspase 3 (n ϭ 3) (A) or the number of annexin V positive HMEC-1 cells (n ϭ 9) (B). (C) Incubation with imatinib in pharmacologically relevant concentrations for 48 hrs did not reduce the metabolic activity of HMEC-1 cells compared with cells incubated with medium only (n ϭ 5). In contrast, incubation with 50% DMSO profoundly reduced the metabolic activity. (D) Imatinib did not reduce proliferation of HMEC-1 cells as analysed by direct cell counting (n ϭ 6).
Apoptosis of endothelial cells in mice treated with imatinib
In summary, we demonstrate that imatinib does not inhibit major functions of endothelial cells. Thus, based on pre-clinical models, the anti-fibrotic activity of imatinib does not seem to be accompanied by unwanted side effects on endothelial cells and imatinib might worsen the pre-existing vascular damage in SSc. 
